RCE · ASX

Recce Pharmaceuticals Ltd. (ASX:RCE)

AU$0.47

 0.01 (2.174%)
ASX:Live
21/11/2024 04:10:42 PM
Hammer Bearish HALO Ords HALO Capital Efficiency GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RCE Overview

RCE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About RCE

Website

Recce Pharmaceuticals Ltd.

Telephone

61.2.9256.2505

Address

Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000

Description

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.

RCE Price Chart

Key Stats

Market Cap

AU$106.66M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.38 - 0.69

Trade Value (12mth)

AU$19,228.00

1 week

-8%

1 month

-15.6%

YTD

-12.38%

1 year

1.1%

All time high

1.86

Key Fundamentals

EPS 3 yr Growth

15.80%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-25.60

Quick Ratio

0.30

Other Data

Shares on Issue (Fully Dilluted)

204m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RCE Announcements

Latest Announcements

Date Announcements

14 November 24

AUD $6.75m R&D Rebate Approved

×

AUD $6.75m R&D Rebate Approved

13 November 24

Notification regarding unquoted securities - RCE

×

Notification regarding unquoted securities - RCE

11 November 24

Ethics Approval for Registrational Ph3 R327G Clinical Trial

×

Ethics Approval for Registrational Ph3 R327G Clinical Trial

06 November 24

AGM Presentation

×

AGM Presentation

06 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

06 November 24

Results of Special General Meeting

×

Results of Special General Meeting

06 November 24

Constitution

×

Constitution

05 November 24

Phase II ABSSSI Clinical Trial Advances to Final Stages

×

Phase II ABSSSI Clinical Trial Advances to Final Stages

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 October 24

Efficacy Data & Approval to Continue Ph II ABSSSI Trial

×

Efficacy Data & Approval to Continue Ph II ABSSSI Trial

09 October 24

Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

×

Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway

08 October 24

Notification of buy-back - RCE

×

Notification of buy-back - RCE

08 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

08 October 24

Notice of Special General Meeting/Proxy Form

×

Notice of Special General Meeting/Proxy Form

26 September 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

26 September 24

Cleansing Notice

×

Cleansing Notice

16 September 24

2024 Annual General Meeting

×

2024 Annual General Meeting

30 August 24

Preliminary Final Report

×

Preliminary Final Report

30 August 24

Annual Report to Shareholders

×

Annual Report to Shareholders

30 August 24

Appendix 4G

×

Appendix 4G

06 August 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

06 August 24

Securities Trading Policy

×

Securities Trading Policy

05 August 24

Successful Completion of Share Purchase Plan

×

Successful Completion of Share Purchase Plan

26 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

15 July 24

US Department of Defense Grants US $2m for R327G

×

US Department of Defense Grants US $2m for R327G

RCE Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.07 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.07 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 27.4 -19.0 -34.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.07 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.07 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.9 -18.5 -21.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.8 -11.7 -12.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.06 -0.01 -0.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.06 -0.01 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.0 -125.6 -224.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 176 176 177 Lock Lock Lock
Basic m Lock Lock Lock Lock 176 176 177 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 17 22 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.5 -15.7 -68.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -14 -17 -22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.3 -22.5 -26.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -14 -17 -22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.9 -22.4 -27.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -14 -17 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -4 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -13 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.7 -19.0 -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -13 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 3 16 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -13 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.1 -40.6 -3.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 2 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 13 3 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -1 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 5 16 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 -3 -10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 -2 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.0 -124.7 -259.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -87.0 -511.7 -277.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -92.0 -444.4 0.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -71.9 -345.3 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -58.9 -335.0 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1,170.8 -93.4 -25.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.8 0.1 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -114.4 50.6 37.8 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.0 0.4 0.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.0 0.4 0.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 95.1 80.2 86.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -368.2 -261.6 -86.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -87.0 -511.7 -277.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 -1.0 -0.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -109.2 505.2 185.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 941.9 1,202.2 2,446.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -941.9 -1,202.2 -2,446.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RCE Shortsell

Frequently Asked Questions

The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.47.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.69.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.38.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.